After the first round of TILA-TACE, significant differences in the CRR were observed according to alpha-fetoprotein (AFP) level, Eastern Cooperative Oncology Group (ECOG) performance status, tumor size, and CNLC stage. This evidence concerns the gene AFP and neoplasm.